NO320441B1 - Nukleosider, oligonukleotidanaloger, farmasoytiske preparater, prober for gener, primere for amplifikasjon og anvendelse av oligonukleotidanaloger til fremstilling av medikamenter - Google Patents

Nukleosider, oligonukleotidanaloger, farmasoytiske preparater, prober for gener, primere for amplifikasjon og anvendelse av oligonukleotidanaloger til fremstilling av medikamenter Download PDF

Info

Publication number: NO320441B1
Authority: NO; Norway
Prior art keywords: group; ethylene; compound; dimethoxytrityl; salts
Prior art date: 1999-02-12

Application number

NO20013899A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013899D0 (no

NO20013899L (no

Inventor

Takeshi Imanishi

Koji Morita

Masakatsu Kaneko

Original Assignee

Sankyo Co

Sankyo Lifetech Company Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-12

Filing date

2001-08-10

Publication date

2005-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12398349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320441(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-08-10 Application filed by Sankyo Co, Sankyo Lifetech Company Ltd filed Critical Sankyo Co

2001-08-10 Publication of NO20013899D0 publication Critical patent/NO20013899D0/no

2001-10-10 Publication of NO20013899L publication Critical patent/NO20013899L/no

2005-12-05 Publication of NO320441B1 publication Critical patent/NO320441B1/no

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 73
108090000623 proteins and genes Proteins 0.000 title claims abstract description 9
230000003321 amplification Effects 0.000 title claims abstract description 8
238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 8
239000000523 sample Substances 0.000 title claims abstract description 7
239000003814 drug Substances 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 5
229940079593 drug Drugs 0.000 title claims description 4
239000000825 pharmaceutical preparation Substances 0.000 title claims description 3
239000002777 nucleoside Substances 0.000 title description 7
125000003835 nucleoside group Chemical group 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 187
-1 2-oxo-pyrimidin-1-yl group Chemical group 0.000 claims abstract description 75
150000003839 salts Chemical class 0.000 claims abstract description 35
125000003277 amino group Chemical group 0.000 claims abstract description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 11
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims abstract description 11
125000001424 substituent group Chemical group 0.000 claims abstract description 10
230000000694 effects Effects 0.000 claims abstract description 9
230000000692 anti-sense effect Effects 0.000 claims abstract description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
150000008300 phosphoramidites Chemical class 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
230000000890 antigenic effect Effects 0.000 claims description 4
239000005977 Ethylene Substances 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
229940045145 uridine Drugs 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 12
125000004432 carbon atom Chemical group C* 0.000 abstract description 11
229910052799 carbon Inorganic materials 0.000 abstract description 7
239000003795 chemical substances by application Substances 0.000 abstract description 7
238000001514 detection method Methods 0.000 abstract description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 6
125000000217 alkyl group Chemical group 0.000 abstract description 6
125000003545 alkoxy group Chemical group 0.000 abstract description 5
239000000543 intermediate Substances 0.000 abstract description 4
229940127073 nucleoside analogue Drugs 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 3
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000005159 cyanoalkoxy group Chemical group 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 236
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 162
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
239000000243 solution Substances 0.000 description 141
238000006243 chemical reaction Methods 0.000 description 100
239000002904 solvent Substances 0.000 description 83
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
239000000203 mixture Substances 0.000 description 78
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 74
238000000034 method Methods 0.000 description 72
229920006395 saturated elastomer Polymers 0.000 description 70
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 69
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 66
239000011541 reaction mixture Substances 0.000 description 66
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
239000012044 organic layer Substances 0.000 description 46
239000000047 product Substances 0.000 description 46
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 44
239000003153 chemical reaction reagent Substances 0.000 description 44
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 41
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
238000004587 chromatography analysis Methods 0.000 description 38
239000007858 starting material Substances 0.000 description 38
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 37
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 35
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
239000000741 silica gel Substances 0.000 description 35
229910002027 silica gel Inorganic materials 0.000 description 35
239000011780 sodium chloride Substances 0.000 description 35
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 33
229910000030 sodium bicarbonate Inorganic materials 0.000 description 33
235000017557 sodium bicarbonate Nutrition 0.000 description 33
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 30
238000005160 1H NMR spectroscopy Methods 0.000 description 27
239000003480 eluent Substances 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 24
239000002585 base Substances 0.000 description 24
230000035484 reaction time Effects 0.000 description 24
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
239000003960 organic solvent Substances 0.000 description 23
238000001035 drying Methods 0.000 description 22
238000001953 recrystallisation Methods 0.000 description 22
238000005406 washing Methods 0.000 description 22
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
150000008282 halocarbons Chemical class 0.000 description 21
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 20
239000012442 inert solvent Substances 0.000 description 20
239000012299 nitrogen atmosphere Substances 0.000 description 20
238000010898 silica gel chromatography Methods 0.000 description 20
239000007787 solid Substances 0.000 description 20
125000006239 protecting group Chemical group 0.000 description 19
239000003054 catalyst Substances 0.000 description 18
239000003638 chemical reducing agent Substances 0.000 description 18
150000002170 ethers Chemical class 0.000 description 18
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 15
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
235000011054 acetic acid Nutrition 0.000 description 15
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 13
150000001408 amides Chemical class 0.000 description 13
239000012230 colorless oil Substances 0.000 description 13
238000010992 reflux Methods 0.000 description 13
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
239000003377 acid catalyst Substances 0.000 description 12
HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 12
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 11
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
150000004945 aromatic hydrocarbons Chemical class 0.000 description 11
125000003118 aryl group Chemical group 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000008096 xylene Substances 0.000 description 11
OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 10
FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
125000002252 acyl group Chemical group 0.000 description 10
150000001298 alcohols Chemical class 0.000 description 10
230000000295 complement effect Effects 0.000 description 10
238000010511 deprotection reaction Methods 0.000 description 10
229940117389 dichlorobenzene Drugs 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
101710163270 Nuclease Proteins 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
230000037396 body weight Effects 0.000 description 8
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 8
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 8
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 8
150000007524 organic acids Chemical class 0.000 description 8
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 7
229910052783 alkali metal Inorganic materials 0.000 description 7
229910021529 ammonia Inorganic materials 0.000 description 7
239000007853 buffer solution Substances 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 7
150000002576 ketones Chemical class 0.000 description 7
YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 7
150000002825 nitriles Chemical class 0.000 description 7
235000005985 organic acids Nutrition 0.000 description 7
229940090181 propyl acetate Drugs 0.000 description 7
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 7
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 7
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 6
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 6
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
125000001931 aliphatic group Chemical group 0.000 description 6
229910000147 aluminium phosphate Inorganic materials 0.000 description 6
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 6
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 6
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 6
125000004430 oxygen atom Chemical group O* 0.000 description 6
239000003208 petroleum Substances 0.000 description 6
150000003003 phosphines Chemical class 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
239000000843 powder Substances 0.000 description 6
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 5
RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
239000007800 oxidant agent Substances 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 4
QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
150000008065 acid anhydrides Chemical class 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
150000008044 alkali metal hydroxides Chemical class 0.000 description 4
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
229910000085 borane Inorganic materials 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
CIXHNHBHWVDBGQ-UHFFFAOYSA-N n-propan-2-ylpropan-2-amine;2h-tetrazole Chemical compound C1=NN=NN1.CC(C)NC(C)C CIXHNHBHWVDBGQ-UHFFFAOYSA-N 0.000 description 4
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
150000003833 nucleoside derivatives Chemical class 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
239000011734 sodium Substances 0.000 description 4
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 4
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
108020004394 Complementary RNA Proteins 0.000 description 3
102000004533 Endonucleases Human genes 0.000 description 3
108010042407 Endonucleases Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
150000008041 alkali metal carbonates Chemical class 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
235000019426 modified starch Nutrition 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
239000012488 sample solution Substances 0.000 description 3
108010062513 snake venom phosphodiesterase I Proteins 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
238000012360 testing method Methods 0.000 description 3
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical class OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
AZYTZQYCOBXDGY-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=CC=N1 AZYTZQYCOBXDGY-UHFFFAOYSA-N 0.000 description 2
UJSALCRAULVQSC-UHFFFAOYSA-N 3-[chloro(morpholin-4-yl)phosphanyl]oxypropanenitrile Chemical compound N#CCCOP(Cl)N1CCOCC1 UJSALCRAULVQSC-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
239000012448 Lithium borohydride Substances 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
101001139139 Penicillium citrinum Nuclease P1 Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000004183 alkoxy alkyl group Chemical group 0.000 description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
238000000137 annealing Methods 0.000 description 2
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
150000004982 aromatic amines Chemical class 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
150000001510 aspartic acids Chemical class 0.000 description 2
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
150000008107 benzenesulfonic acids Chemical class 0.000 description 2
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
238000009835 boiling Methods 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 2
DXHPZXWIPWDXHJ-UHFFFAOYSA-N carbon monosulfide Chemical compound [S+]#[C-] DXHPZXWIPWDXHJ-UHFFFAOYSA-N 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
QRZIAPZXZKAHMT-UHFFFAOYSA-N chloro(morpholin-4-ylmethoxy)phosphane Chemical compound ClPOCN1CCOCC1 QRZIAPZXZKAHMT-UHFFFAOYSA-N 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
229940117975 chromium trioxide Drugs 0.000 description 2
WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
150000001868 cobalt Chemical class 0.000 description 2
150000001879 copper Chemical class 0.000 description 2
238000007333 cyanation reaction Methods 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
150000005332 diethylamines Chemical class 0.000 description 2
229940043279 diisopropylamine Drugs 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
150000002301 glucosamine derivatives Chemical class 0.000 description 2
150000002332 glycine derivatives Chemical class 0.000 description 2
150000002357 guanidines Chemical class 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
159000000014 iron salts Chemical class 0.000 description 2
DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 description 2
229910003002 lithium salt Inorganic materials 0.000 description 2
159000000002 lithium salts Chemical class 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000002688 maleic acid derivatives Chemical class 0.000 description 2
150000004701 malic acid derivatives Chemical class 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000011259 mixed solution Substances 0.000 description 2
150000002780 morpholines Chemical class 0.000 description 2
CXLVBVPYZYXEFY-UHFFFAOYSA-N n-(chlorophosphanyloxymethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)COPCl CXLVBVPYZYXEFY-UHFFFAOYSA-N 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
150000002815 nickel Chemical class 0.000 description 2
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
150000003016 phosphoric acids Chemical class 0.000 description 2
150000004885 piperazines Chemical class 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
150000003222 pyridines Chemical class 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000001226 reprecipitation Methods 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
150000003892 tartrate salts Chemical class 0.000 description 2
238000010998 test method Methods 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000011701 zinc Substances 0.000 description 2
150000003751 zinc Chemical class 0.000 description 2
JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
BJLINASJLIKIMM-XVMARJQXSA-N 1-[(2r,4s,5s)-5-(dihydroxymethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](C(O)O)[C@@H](O)C1 BJLINASJLIKIMM-XVMARJQXSA-N 0.000 description 1
VWCUMTCXBIRRSG-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2-methoxybenzene Chemical compound COC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 VWCUMTCXBIRRSG-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
ARAKSJFGTUYKFI-UHFFFAOYSA-N 1-chlorophosphanyloxy-n,n-dimethylmethanamine Chemical compound CN(C)COPCl ARAKSJFGTUYKFI-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
AAYWIXGLVAEPTP-UHFFFAOYSA-N 2,3-dimethylbutan-2-ylboron Chemical compound [B]C(C)(C)C(C)C AAYWIXGLVAEPTP-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XSLACWHPRWNAHR-FATASBFNSA-N 2-amino-9-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(2-methylpropanoyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@]1(C(=O)C(C)C)O[C@H](CO)[C@@H](O)[C@H]1O XSLACWHPRWNAHR-FATASBFNSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
LQIIEHBULBHJKX-UHFFFAOYSA-N 2-methylpropylalumane Chemical compound CC(C)C[AlH2] LQIIEHBULBHJKX-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
DNWDZSHXZYWCKL-UHFFFAOYSA-N 3-[chloro(dimethylamino)phosphanyl]oxypropanenitrile Chemical compound CN(C)P(Cl)OCCC#N DNWDZSHXZYWCKL-UHFFFAOYSA-N 0.000 description 1
ZTRXFCGYDLPIDD-UHFFFAOYSA-N 4-amino-1-benzoylpyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C(=O)C1=CC=CC=C1 ZTRXFCGYDLPIDD-UHFFFAOYSA-N 0.000 description 1
RKUTUPWSNNOZOF-UHFFFAOYSA-N 4-methylpentan-2-one;3,5,5-trimethylcyclohex-2-en-1-one Chemical compound CC(C)CC(C)=O.CC1=CC(=O)CC(C)(C)C1 RKUTUPWSNNOZOF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000764238 Isis Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
238000003527 Peterson olefination reaction Methods 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
VTAPXODOLMOLNK-PCYKNENESA-N [(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-phenylmethanone Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C(=O)C=2C=CC=CC=2)O[C@H](CO)[C@@H](O)[C@H]1O VTAPXODOLMOLNK-PCYKNENESA-N 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000001243 acetic acids Chemical class 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
229940095602 acidifiers Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
VOZYXUHNEBULJT-UHFFFAOYSA-N aluminum oxygen(2-) rhodium(3+) Chemical compound [O--].[O--].[O--].[Al+3].[Rh+3] VOZYXUHNEBULJT-UHFFFAOYSA-N 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
239000012043 crude product Substances 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
238000006642 detritylation reaction Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229960005215 dichloroacetic acid Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HXJFQNUWPUICNY-UHFFFAOYSA-N disiamylborane Chemical compound CC(C)C(C)BC(C)C(C)C HXJFQNUWPUICNY-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
SBBFZWWBMFILKH-UHFFFAOYSA-N ethanesulfonyl bromide Chemical compound CCS(Br)(=O)=O SBBFZWWBMFILKH-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
150000004674 formic acids Chemical class 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011968 lewis acid catalyst Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
FMKLITBCOZWOEX-UHFFFAOYSA-N n-(5-methyl-2-oxo-1h-pyrimidin-6-yl)benzamide Chemical compound CC1=CNC(=O)N=C1NC(=O)C1=CC=CC=C1 FMKLITBCOZWOEX-UHFFFAOYSA-N 0.000 description 1
BZXPRAMDDLELPW-UHFFFAOYSA-N n-[(4-chlorophenyl)methoxy-[di(propan-2-yl)amino]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCC1=CC=C(Cl)C=C1 BZXPRAMDDLELPW-UHFFFAOYSA-N 0.000 description 1
UJWFQQZVNADDHW-UHFFFAOYSA-N n-[[di(propan-2-yl)amino]-(2,2,2-trichloroethoxy)phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCC(Cl)(Cl)Cl UJWFQQZVNADDHW-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
125000005499 phosphonyl group Chemical group 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
108091033319 polynucleotide Chemical class 0.000 description 1
239000002157 polynucleotide Chemical class 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
150000004672 propanoic acids Chemical class 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
125000005624 silicic acid group Chemical class 0.000 description 1
NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
FEQPHYCEZKWPNE-UHFFFAOYSA-K trichlororhodium;triphenylphosphane Chemical compound Cl[Rh](Cl)Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FEQPHYCEZKWPNE-UHFFFAOYSA-K 0.000 description 1
GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Plant Pathology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO20013899A 1999-02-12 2001-08-10 Nukleosider, oligonukleotidanaloger, farmasoytiske preparater, prober for gener, primere for amplifikasjon og anvendelse av oligonukleotidanaloger til fremstilling av medikamenter NO320441B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP3386399		1999-02-12
PCT/JP2000/000725 WO2000047599A1 (fr)	1999-02-12	2000-02-10	Nouveaux analogues de nucleosides et d'oligonucleotides

Publications (3)

Publication Number	Publication Date
NO20013899D0 NO20013899D0 (no)	2001-08-10
NO20013899L NO20013899L (no)	2001-10-10
NO320441B1 true NO320441B1 (no)	2005-12-05

Family

ID=12398349

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013899A NO320441B1 (no)	1999-02-12	2001-08-10	Nukleosider, oligonukleotidanaloger, farmasoytiske preparater, prober for gener, primere for amplifikasjon og anvendelse av oligonukleotidanaloger til fremstilling av medikamenter

Country Status (26)

Country	Link
US (4)	US7335765B2 (tr)
EP (1)	EP1152009B2 (tr)
JP (1)	JP3420984B2 (tr)
KR (1)	KR100573231B1 (tr)
CN (1)	CN1273478C (tr)
AT (1)	ATE287897T2 (tr)
AU (1)	AU758956B2 (tr)
BR (1)	BRPI0008131B8 (tr)
CA (1)	CA2361318C (tr)
CZ (1)	CZ296576B6 (tr)
DE (1)	DE60017711T3 (tr)
DK (1)	DK1152009T4 (tr)
ES (1)	ES2234563T5 (tr)
HK (1)	HK1040084B (tr)
HU (1)	HU228398B1 (tr)
ID (1)	ID30093A (tr)
IL (2)	IL144338A0 (tr)
NO (1)	NO320441B1 (tr)
NZ (1)	NZ513402A (tr)
PL (1)	PL208245B1 (tr)
PT (1)	PT1152009E (tr)
RU (1)	RU2233844C2 (tr)
TR (2)	TR200102328T2 (tr)
TW (1)	TW513438B (tr)
WO (1)	WO2000047599A1 (tr)
ZA (1)	ZA200106544B (tr)

Families Citing this family (454)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
JP4148662B2 (ja) *	2000-08-10	2008-09-10	第一三共株式会社	ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
JP4151751B2 (ja) *	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
JP4413493B2 (ja)	2000-10-04	2010-02-10	サンタリスファーマアー／エス	プリンｌｎａ類似体の改善された合成方法
GB0114719D0 (en) *	2001-06-15	2001-08-08	Glaxo Group Ltd	Compound
WO2003033696A1 (fr) *	2001-10-18	2003-04-24	Sankyo Company, Limited	Compose antisens vegf
EP1481983A4 (en)	2002-02-13	2008-04-02	Takeshi Imanishi	NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
CA2504929C (en)	2002-11-05	2014-07-22	Charles Allerson	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7696345B2 (en)	2002-11-05	2010-04-13	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2013201786B2 (en) *	2002-11-18	2015-04-02	Roche Innovation Center Copenhagen A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
DK2284269T3 (en) *	2002-11-18	2017-10-23	Roche Innovation Ct Copenhagen As	Antisense design
JP5132025B2 (ja) *	2002-11-19	2013-01-30	第一三共株式会社	新規２’，５’−オリゴアデニル酸類縁体
TWI347948B (en) *	2002-11-19	2011-09-01	Sankyo Co	Novel 2',5'-oligoadenylic acid compositions
AU2003284638A1 (en)	2002-11-25	2004-06-18	Nonprofit Organization Translational Research Organization Of Duchenne Muscular Dystrophy	ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR
ATE553216T1 (de)	2003-06-20	2012-04-15	Exiqon As	Sonden, bibliotheken und kits zur analyse von nukleinsäuregemischen und verfahren zu deren konstruktion
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005021570A1 (ja) *	2003-08-28	2005-03-10	Gene Design, Inc.	Ｎ−０結合性架橋構造型新規人工核酸
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US7480382B2 (en) *	2003-09-30	2009-01-20	Microsoft Corporation	Image file container
GB0324854D0 (en) *	2003-10-24	2003-11-26	Expresson Biosystems Ltd	App/ena antisense
EP1688493B1 (en) *	2003-11-07	2008-08-13	Daiichi Sankyo Company, Limited	Method of detecting genetic polymorphism
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1783216A1 (en) *	2004-05-28	2007-05-09	Sankyo Company, Limited	Telomerase-inhibitory ena oligonucleotide
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006059507A1 (ja) *	2004-11-30	2006-06-08	Sankyo Company, Limited	11β-HSD1アンチセンス化合物
US20060257902A1 (en) *	2005-03-25	2006-11-16	Ambion, Inc.	Methods and compositions for depleting abundant RNA transcripts
EP1931780B1 (en)	2005-08-29	2016-01-06	Regulus Therapeutics Inc.	Antisense compounds having enhanced anti-microrna activity
US9862770B2 (en)	2005-10-19	2018-01-09	Ibc Pharmaceuticals, Inc.	Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en)	2009-01-20	2010-09-09	Immunomedics, Inc.	Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US8883162B2 (en) *	2005-10-19	2014-11-11	Ibc Pharmaceuticals, Inc.	Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
EP1971371B1 (en)	2005-12-01	2015-08-05	Pronai Therapeutics, Inc.	Cancer therapies and pharmaceutical compositions used therein
KR101404374B1 (ko) *	2005-12-09	2014-06-09	도꾸리쯔교세이호징 리가가쿠 겐큐소	핵산의 복제방법 및 신규한 인공 염기쌍
WO2007087113A2 (en)	2005-12-28	2007-08-02	The Scripps Research Institute	Natural antisense and non-coding rna transcripts as drug targets
CN102908630B (zh)	2006-01-27	2014-11-19	Isis制药公司	6-修饰的双环核酸类似物
CA2640058C (en)	2006-01-27	2018-04-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
EP2527442A3 (en)	2006-05-05	2013-03-06	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating gene expression
WO2007136988A2 (en) *	2006-05-05	2007-11-29	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of gccr
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
EP2410053B2 (en)	2006-10-18	2020-07-15	Ionis Pharmaceuticals, Inc.	Antisense compounds
TW200838551A (en) *	2006-11-27	2008-10-01	Isis Pharmaceuticals Inc	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US20100292301A1 (en) *	2007-02-28	2010-11-18	Elena Feinstein	Novel sirna structures
WO2008150729A2 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
EP2173358B1 (en) *	2007-06-22	2015-10-21	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
EP2176280B2 (en)	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
MX2010003465A (es)	2007-10-02	2010-07-05	Amgen Inc	Incremento de eritropoyetina utilizando acidos nucleicos que hibridan para micro-arn y precursores de los mismos.
US8614309B2 (en) *	2007-10-03	2013-12-24	Quark Pharmaceuticals, Inc.	Double-stranded RNA directed to CASP2 and methods of use thereof
WO2009067647A1 (en) *	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
US20110105584A1 (en) *	2007-12-12	2011-05-05	Elena Feinstein	Rtp80il sirna compounds and methods of use thereof
US8614311B2 (en)	2007-12-12	2013-12-24	Quark Pharmaceuticals, Inc.	RTP801L siRNA compounds and methods of use thereof
WO2009090639A2 (en) *	2008-01-15	2009-07-23	Quark Pharmaceuticals, Inc.	Sirna compounds and methods of use thereof
WO2009100320A2 (en)	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
US10131904B2 (en)	2008-02-11	2018-11-20	Rxi Pharmaceuticals Corporation	Modified RNAi polynucleotides and uses thereof
WO2009116037A2 (en) *	2008-03-20	2009-09-24	Quark Pharmaceuticals, Inc.	NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
DK2285819T3 (da)	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
US8278287B2 (en) *	2008-04-15	2012-10-02	Quark Pharmaceuticals Inc.	siRNA compounds for inhibiting NRF2
US8222221B2 (en)	2008-06-04	2012-07-17	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small RNA targeting of gene promoters
EP2293800B1 (en)	2008-06-06	2016-10-05	Quark Pharmaceuticals, Inc.	Compositions and methods for treatment of ear disorders
TWI455944B (zh)	2008-07-01	2014-10-11	Daiichi Sankyo Co Ltd	雙股多核苷酸
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
WO2010014592A1 (en)	2008-07-29	2010-02-04	The Board Of Regents Of The University Of Texas Sytem	Selective inhibition of polyglutamine protein expression
EP3081648A1 (en) *	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2010033247A2 (en)	2008-09-22	2010-03-25	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
EP2356129B1 (en)	2008-09-24	2013-04-03	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
CA2739464C (en) *	2008-10-03	2020-03-31	Opko Curna, Llc	Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
US9074211B2 (en)	2008-11-19	2015-07-07	Rxi Pharmaceuticals Corporation	Inhibition of MAP4K4 through RNAI
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
WO2010065671A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CN102317458B (zh)	2008-12-04	2018-01-02	库尔纳公司	通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
AU2009335740B2 (en)	2008-12-17	2016-04-21	Sarepta Therapeutics, Inc.	Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010080452A2 (en)	2008-12-18	2010-07-15	Quark Pharmaceuticals, Inc.	siRNA COMPOUNDS AND METHODS OF USE THEREOF
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP3009150B1 (en)	2009-02-12	2019-11-13	CuRNA, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9464287B2 (en)	2009-03-16	2016-10-11	Curna, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
EP2408920B1 (en)	2009-03-17	2017-03-08	CuRNA, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010124231A2 (en)	2009-04-24	2010-10-28	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
DE102009019476A1 (de) *	2009-05-04	2010-11-11	Biametrics Marken Und Rechte Gmbh	Wiedererkennbarer Träger für optische Meßverfahren
EP2427553A4 (en)	2009-05-06	2012-11-07	Opko Curna Llc	TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
CA2761142C (en)	2009-05-06	2021-06-08	Opko Curna, Llc	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CA3185821A1 (en)	2009-05-08	2010-11-11	Curna, Inc.	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
NO2432881T3 (tr)	2009-05-18	2018-04-14
US8895527B2 (en)	2009-05-22	2014-11-25	Curna, Inc.	Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
ES2618576T3 (es)	2009-05-28	2017-06-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
CA2763537A1 (en)	2009-06-08	2010-12-16	Quark Pharmaceuticals, Inc.	Methods for treating chronic kidney disease
CA2765509C (en)	2009-06-16	2021-08-17	Joseph Collard	Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
KR101801404B1 (ko)	2009-06-16	2017-12-20	큐알엔에이, 인크.	콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en)	2009-07-24	2018-06-19	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP2462229B1 (en)	2009-08-05	2016-05-11	CuRNA, Inc.	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
KR101827015B1 (ko)	2009-08-11	2018-02-07	큐알엔에이, 인크.	아디포넥틴(ａｄｉｐｏｑ)에 대한 천연 안티센스 전사체의 억제에 의한 아디포넥틴(ａｄｉｐｏｑ) 관련된 질환의 치료
WO2011022606A2 (en)	2009-08-21	2011-02-24	Curna, Inc.	Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en)	2009-08-25	2011-03-17	Curna, Inc.	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2664591T3 (es)	2009-09-25	2018-04-20	Curna, Inc.	Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
WO2011052715A1 (ja)	2009-10-30	2011-05-05	第一三共株式会社	修飾２本鎖ポリヌクレオチド
WO2011053994A1 (en)	2009-11-02	2011-05-05	Alnylam Pharmaceuticals, Inc.	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
WO2011072091A1 (en)	2009-12-09	2011-06-16	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the cns
CN102741410B (zh)	2009-12-09	2016-11-16	日东电工株式会社	Hsp47表达的调节
EP2513310B1 (en)	2009-12-16	2017-11-01	CuRNA, Inc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
CA2782375C (en)	2009-12-23	2023-10-31	Opko Curna, Llc	Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
KR101891352B1 (ko)	2009-12-23	2018-08-24	큐알엔에이, 인크.	간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
EP2519633B1 (en)	2009-12-29	2017-10-25	CuRNA, Inc.	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
RU2611186C2 (ru)	2009-12-29	2017-02-21	Курна, Инк.	ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
RU2016115782A (ru)	2009-12-31	2018-11-28	Курна, Инк.	Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
CN102822342B (zh)	2010-01-06	2017-05-10	库尔纳公司	通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
WO2011084193A1 (en)	2010-01-07	2011-07-14	Quark Pharmaceuticals, Inc.	Oligonucleotide compounds comprising non-nucleotide overhangs
ES2664866T3 (es)	2010-01-11	2018-04-23	Curna, Inc.	Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
KR20130008560A (ko)	2010-03-12	2013-01-22	다이이찌 산쿄 가부시키가이샤	마이크로 ｒｎａ를 이용한 심근 세포의 증식 방법
US9193752B2 (en)	2010-03-17	2015-11-24	Isis Pharmaceuticals, Inc.	5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
WO2011119871A1 (en)	2010-03-24	2011-09-29	Rxi Phrmaceuticals Corporation	Rna interference in ocular indications
EP2550002B1 (en)	2010-03-24	2019-05-08	Phio Pharmaceuticals Corp.	Rna interference in dermal and fibrotic indications
KR101877065B1 (ko)	2010-04-02	2018-07-10	큐알엔에이, 인크.	집락 자극 인자 3 (ｃｓｆ3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (ｃｓｆ3) 관련된 질환의 치료
CA2795281A1 (en)	2010-04-09	2011-10-13	Curna, Inc.	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
EP2601204B1 (en)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
EP2957636B1 (en)	2010-05-03	2020-04-01	CuRNA, Inc.	Treatment of sirtuin 3 (sirt3) related diseases by inhibition of natural antisense transcript to sirt3
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
NO2576784T3 (tr)	2010-05-26	2018-04-14
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2863526T3 (es)	2010-06-23	2021-10-11	Curna Inc	Tratamiento de enfermedades relacionadas con la subunidad alfa del canal de sodio (SCNA), controlado por voltaje, mediante inhibición de la transcripción antisentido natural a SCNA
WO2012009402A2 (en)	2010-07-14	2012-01-19	Opko Curna Llc	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
EP2412724A1 (en)	2010-07-29	2012-02-01	Centre National de la Recherche Scientifique (C.N.R.S)	Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
RU2624048C2 (ru)	2010-10-06	2017-06-30	Курна, Инк.	Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
WO2012068340A2 (en)	2010-11-18	2012-05-24	Opko Curna Llc	Antagonat compositions and methods of use
CN103459599B (zh)	2010-11-23	2017-06-16	库尔纳公司	通过抑制nanog的天然反义转录物而治疗nanog相关疾病
RU2013129999A (ru)	2010-12-02	2015-01-10	Дайити Санкио Компани, Лимитед	Модифицированный одноцепочечный полинуклеотид
EP3467109A1 (en)	2011-02-08	2019-04-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9796979B2 (en)	2011-03-03	2017-10-24	Quark Pharmaceuticals Inc.	Oligonucleotide modulators of the toll-like receptor pathway
SG192961A1 (en)	2011-03-03	2013-09-30	Quark Pharmaceuticals Inc	Compositions and methods for treating lung disease and injury
SG10201604479YA (en)	2011-03-03	2016-07-28	Quark Pharmaceuticals Inc	Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
US9273366B2 (en)	2011-06-15	2016-03-01	Grifols Therapeutics Inc.	Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
WO2013022990A1 (en)	2011-08-11	2013-02-14	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP2753317B1 (en)	2011-09-06	2020-02-26	CuRNA, Inc.	TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
WO2013040429A1 (en)	2011-09-14	2013-03-21	Rana Therapeutics Inc.	Multimeric oligonucleotide compounds
WO2013067076A2 (en)	2011-11-03	2013-05-10	Quark Pharmaceuticals, Inc.	Methods and compositions for neuroprotection
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
WO2013119602A1 (en)	2012-02-06	2013-08-15	President And Fellows Of Harvard College	Arrdc1-mediated microvesicles (armms) and uses thereof
CN104583405A (zh)	2012-03-15	2015-04-29	科纳公司	通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
AU2013203395A1 (en)	2012-03-30	2013-10-17	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
EP3336189A1 (en)	2012-04-20	2018-06-20	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20150133362A1 (en)	2012-05-16	2015-05-14	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
CN104540947A (zh)	2012-05-16	2015-04-22	Rana医疗有限公司	用于调节smn基因家族表达的组合物和方法
CA2873779A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics Inc.	Compositions and methods for modulating mecp2 expression
JP2013256452A (ja) *	2012-06-11	2013-12-26	Kawaken Fine Chem Co Ltd	メラニン産生抑制剤とその組成物
WO2013191129A1 (ja)	2012-06-18	2013-12-27	第一三共株式会社	ヌクレオシド類縁体の製造中間体及びその製造方法
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US20150299803A1 (en)	2012-11-05	2015-10-22	Pronai Therapeutics, Inc.	Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
WO2014134179A1 (en)	2013-02-28	2014-09-04	The Board Of Regents Of The University Of Texas System	Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014143158A1 (en)	2013-03-13	2014-09-18	The Broad Institute, Inc.	Compositions and methods for labeling of agents
US9273349B2 (en)	2013-03-14	2016-03-01	Affymetrix, Inc.	Detection of nucleic acids
WO2014153236A1 (en)	2013-03-14	2014-09-25	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating tau expression
WO2014176259A1 (en)	2013-04-22	2014-10-30	Icahn School Of Medicine At Mount Sinai	Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
CN105378085B (zh)	2013-05-01	2019-02-15	Ionis制药公司	用于调节hbv和ttr表达的组合物和方法
TWI772856B (zh)	2013-07-19	2022-08-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
JP2016534035A (ja)	2013-10-04	2016-11-04	ラナセラピューティクスインコーポレイテッド	筋萎縮性側索硬化症を治療するための組成物及び方法
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015075166A1 (en)	2013-11-22	2015-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of a bacterial infection
US10934550B2 (en)	2013-12-02	2021-03-02	Phio Pharmaceuticals Corp.	Immunotherapy of cancer
EP3099798B1 (en)	2014-01-29	2018-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
ES2818236T3 (es)	2014-04-01	2021-04-09	Biogen Ma Inc	Composiciones para modular la expresión de SOD-1
EP3647318B1 (en)	2014-04-28	2021-06-30	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
EA036496B1 (ru)	2014-05-01	2020-11-17	Ионис Фармасьютикалз, Инк.	Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016017422A1 (ja) *	2014-07-31	2016-02-04	国立大学法人大阪大学	架橋型ヌクレオシドおよびヌクレオチド
IL234246A0 (en)	2014-08-21	2014-11-30	Omrix Biopharmaceuticals Ltd	Stabilized thrombin
CN107073294A (zh)	2014-09-05	2017-08-18	阿克赛医药公司	使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
SG11201702682PA (en)	2014-10-03	2017-04-27	Cold Spring Harbor Lab	Targeted augmentation of nuclear gene output
US9816080B2 (en)	2014-10-31	2017-11-14	President And Fellows Of Harvard College	Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
AU2015364508A1 (en)	2014-12-18	2017-07-06	Alnylam Pharmaceuticals, Inc.	ReversirTM compounds
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US11001845B2 (en)	2015-07-06	2021-05-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
AU2016295168B2 (en)	2015-07-17	2021-08-19	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
DK3341479T3 (da)	2015-08-24	2020-02-24	Roche Innovation Ct Copenhagen As	LNA-G-Proces
KR20220105174A (ko)	2015-10-09	2022-07-26	유니버시티 오브 사우스앰톤	유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
JP2018531037A (ja)	2015-10-19	2018-10-25	アールエックスアイファーマシューティカルズコーポレーション	長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
EP3371211A4 (en)	2015-11-04	2019-08-21	Icahn School of Medicine at Mount Sinai	METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
SI4220360T1 (sl)	2015-11-12	2024-10-30	F. Hoffmann - La Roche Ag	Oligonukleotidi za indukcijo očetovske ekspresije UBE3A
EP3389670A4 (en)	2015-12-04	2020-01-08	Ionis Pharmaceuticals, Inc.	METHODS OF TREATING BREAST CANCER
EP3933041B1 (en)	2015-12-14	2024-01-31	Cold Spring Harbor Laboratory	Antisense oligomers for treatment of autosomal dominant retardation
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
JOP20200228A1 (ar)	2015-12-21	2017-06-16	Novartis Ag	تركيبات وطرق لخفض تعبير البروتين tau
ES2857702T3 (es)	2016-03-14	2021-09-29	Hoffmann La Roche	Oligonucleótidos para la reducción de la expresión de PD-L1
CA3013799A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
EP3442983A1 (en)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
WO2017189730A1 (en)	2016-04-26	2017-11-02	Icahn School Of Medicine At Mount Sinai	Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2017219017A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
MA45496A (fr)	2016-06-17	2019-04-24	Hoffmann La Roche	Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
AU2017289204A1 (en)	2016-07-01	2019-01-17	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating HTRA1 expression
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CA3030701A1 (en)	2016-07-11	2018-01-18	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
WO2018053185A1 (en)	2016-09-14	2018-03-22	Alios Biopharma, Inc.	Modified oligonucleotides and methods of use
JOP20190065A1 (ar)	2016-09-29	2019-03-28	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن tau
US11730823B2 (en)	2016-10-03	2023-08-22	President And Fellows Of Harvard College	Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
JP7033591B2 (ja)	2016-11-11	2022-03-10	ロシュイノベーションセンターコペンハーゲンエーエス	治療用オリゴヌクレオチドの捕捉および検出
EP3548620A4 (en)	2016-12-02	2020-07-22	Cold Spring Harbor Laboratory	MODULATION OF THE EXPRESSION OF LNC05
US11230709B2 (en)	2016-12-28	2022-01-25	National University Corporation Kobe University	Therapeutic drug for Alport's syndrome
CA3045045A1 (en)	2017-01-10	2018-07-19	Zhen Li	Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
WO2018130583A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb1 expression
EP3568481A1 (en)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
EP3568477A1 (en)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rela expression
WO2018130582A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rel expression
US20190345495A1 (en)	2017-01-13	2019-11-14	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb2 expression
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
WO2018164275A1 (ja)	2017-03-10	2018-09-13	国立研究開発法人国立成育医療研究センター	アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
US11377468B2 (en)	2017-03-10	2022-07-05	Lakewood Amedex, Inc.	Antimicrobial compounds, compositions, and uses thereof
BR112019018615B1 (pt)	2017-03-10	2021-11-16	Lakewood Amedex, Inc.	Composto antimicrobiano e sua composiqao farmaceutica
US11795192B2 (en)	2017-03-10	2023-10-24	Lakewood Amedex, Inc.	Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en)	2017-03-10	2024-07-09	Lakewood Amedex, Inc.	Antimicrobial compounds, compositions, and uses thereof
US11479769B2 (en)	2017-03-17	2022-10-25	National University Corporation Chiba University	Technique for treating cancer using structurally-reinforced S-TuD
JP7246729B2 (ja)	2017-05-18	2023-03-28	国立大学法人京都大学	脊髄小脳変性症３６型の予防又は治療用組成物
US20190055564A1 (en)	2017-06-01	2019-02-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating htra1 expression
JPWO2019009299A1 (ja)	2017-07-05	2020-05-07	国立大学法人大阪大学	α−シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
WO2019013141A1 (ja)	2017-07-10	2019-01-17	国立大学法人大阪大学	Ｔｄｐ－４３の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
AU2018318231A1 (en)	2017-08-18	2020-02-13	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
WO2019040923A1 (en)	2017-08-25	2019-02-28	Stoke Therapeutics, Inc.	ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASE CONDITIONS AND OTHER DISEASES
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
CN118345073A (zh)	2017-09-14	2024-07-16	詹森生物制药有限公司	GalNAc衍生物
JP2021502059A (ja)	2017-10-13	2021-01-28	ロシュイノベーションセンターコペンハーゲンエーエス	部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
BR112020007417A2 (pt)	2017-10-16	2021-01-26	F. Hoffmann-La Roche Ag	molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b
EP3697904A1 (en)	2017-10-17	2020-08-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination treatment for cystic fibrosis
WO2019111791A1 (ja) *	2017-12-07	2019-06-13	第一三共株式会社	ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
WO2019115416A2 (en)	2017-12-11	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
WO2019121838A1 (en)	2017-12-21	2019-06-27	F. Hoffmann-La Roche Ag	Companion diagnostic for htra1 rna antagonists
CN111757936A (zh)	2017-12-22	2020-10-09	罗氏创新中心哥本哈根有限公司	包含二硫代磷酸酯核苷间连接的寡核苷酸
EP4092118A1 (en)	2017-12-22	2022-11-23	Roche Innovation Center Copenhagen A/S	Novel thiophosphoramidites
MX2020005754A (es)	2017-12-22	2020-08-20	Roche Innovation Ct Copenhagen As	Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
US20210095274A1 (en)	2018-01-10	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating pias4 expression
MX2020006973A (es)	2018-01-12	2020-09-09	Roche Innovation Ct Copenhagen As	Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos.
US20210095275A1 (en)	2018-01-12	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
BR112020014011A2 (pt)	2018-01-12	2020-12-08	Bristol-Myers Squibb Company	Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos
CN111836624A (zh)	2018-01-12	2020-10-27	百时美施贵宝公司	靶向α-突触核蛋白的反义寡核苷酸及其用途
US20210095276A1 (en)	2018-01-17	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating erc1 expression
JP2021511029A (ja)	2018-01-18	2021-05-06	ロシュイノベーションセンターコペンハーゲンエーエス	Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
CR20200346A (es)	2018-02-09	2020-10-19	Genentech Inc	Oligonucleótidos para modular la expresión de tmem106b
CN112020559A (zh)	2018-02-21	2020-12-01	百时美施贵宝公司	Camk2d反义寡核苷酸及其用途
CN111511915A (zh)	2018-03-09	2020-08-07	第一三共株式会社	糖原病Ia型治疗药
EP3765476A2 (en)	2018-03-13	2021-01-20	Janssen Pharmaceutica NV	Modified oligonucleotides for use in treatment of tauopathies
AU2019247645A1 (en)	2018-04-05	2020-10-15	Centre Leon Berard	Use of FUBP1 inhibitors for treating hepatitis B virus infection
US12060558B2 (en)	2018-05-04	2024-08-13	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
JP7353301B2 (ja)	2018-05-07	2023-09-29	アルニラムファーマスーティカルズインコーポレイテッド	肝臓外送達
US20220002796A1 (en)	2018-05-07	2022-01-06	Roche Innovation Center Copenhagen A/S	Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
US20210371860A1 (en)	2018-05-08	2021-12-02	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating myh7 expression
US20210220387A1 (en)	2018-05-18	2021-07-22	Hoffmann-La Roche, Inc.	Pharmaceutical compositions for treatment of microrna related diseases
WO2019224172A1 (en)	2018-05-25	2019-11-28	Roche Innovation Center Copenhagen A/S	Novel process for making allofuranose from glucofuranose
WO2019233921A1 (en)	2018-06-05	2019-12-12	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating atxn2 expression
US20210207136A1 (en)	2018-06-13	2021-07-08	Daiichi Sankyo Company, Limited	Myocardial dysfunction therapeutic agent
WO2019246112A1 (en)	2018-06-18	2019-12-26	University Of Rochester	Methods of treating schizophrenia and other neuropsychiatric disorders
US20220062378A1 (en)	2018-06-21	2022-03-03	University Of Rochester	Methods of treating or inhibiting onset of huntington's disease
WO2020007702A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting spi1
WO2020007772A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting gbp-1
CR20210058A (es)	2018-07-03	2021-03-22	Hoffmann La Roche	Oligonucleótidos para modular la expresión de tau
WO2020009151A1 (ja)	2018-07-04	2020-01-09	国立大学法人名古屋大学	タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途
WO2020007826A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mbtps1
WO2020007889A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting stat1
WO2020011743A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mafb
WO2020011653A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting kynu
WO2020011744A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers5
WO2020011869A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting tlr2
WO2020011745A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers6
CR20210015A (es)	2018-07-13	2021-03-22	Hoffmann La Roche	Oligonucleótidos para modular la expresión de rtel 1
MX2020013270A (es)	2018-07-31	2021-02-18	Roche Innovation Ct Copenhagen As	Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
EP4122943B1 (en)	2018-07-31	2024-05-29	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
US12097263B2 (en)	2018-08-02	2024-09-24	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en)	2018-08-02	2024-02-27	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020038968A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Microrna-134 biomarker
WO2020038973A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting sptlc1
WO2020038971A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting vcan
WO2020038976A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting usp8
CN113728102A (zh)	2018-08-28	2021-11-30	罗氏创新中心哥本哈根有限公司	使用剪接调节化合物进行新抗原工程化
EP3620519A1 (en)	2018-09-04	2020-03-11	F. Hoffmann-La Roche AG	Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
MX2021004396A (es)	2018-10-17	2021-06-04	Lakewood Amedex Inc	Metodos y composiciones para el tratamiento de la mucositis oral.
EP3873920A1 (en)	2018-11-01	2021-09-08	F. Hoffmann-La Roche AG	Antisense oligonucleotides targeting tia1
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EA202191342A1 (ru)	2018-11-15	2021-08-10	Айонис Фармасьютикалз, Инк.	Модуляторы экспрессии irf5
WO2020104492A1 (en)	2018-11-22	2020-05-28	Roche Innovation Center Copenhagen A/S	Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
WO2020109344A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Occular administration device for antisense oligonucleotides
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
CA3122289A1 (en)	2018-12-11	2020-06-18	University Of Rochester	Methods of treating schizophrenia and other neuropsychiatric disorders
EP3898975A2 (en)	2018-12-21	2021-10-27	Boehringer Ingelheim International GmbH	Antisense oligonucleotides targeting card9
WO2020152303A1 (en)	2019-01-25	2020-07-30	F. Hoffmann-La Roche Ag	Lipid vesicle for oral drug delivery
AU2020216444A1 (en) *	2019-01-31	2021-07-29	Ionis Pharmaceuticals, Inc.	Modulators of YAP1 expression
WO2020167822A2 (en)	2019-02-13	2020-08-20	University Of Rochester	Gene networks that mediate remyelination of the human brain
WO2020169696A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Novel phosphoramidites
EP3927826A1 (en)	2019-02-20	2021-12-29	Roche Innovation Center Copenhagen A/S	Phosphonoacetate gapmer oligonucleotides
EP3931348B1 (en)	2019-02-26	2023-08-09	Roche Innovation Center Copenhagen A/S	Oligonucleotide formulation method
JP7492526B2 (ja)	2019-02-27	2024-05-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍａｌａｔ１発現のモジュレーター
EP3934695A1 (en)	2019-03-05	2022-01-12	F. Hoffmann-La Roche AG	Intracellular targeting of molecules
MX2021011242A (es)	2019-03-21	2022-01-19	Codiak Biosciences Inc	Conjugados de vesícula extracelular y usos de estos.
WO2020203896A1 (ja)	2019-03-29	2020-10-08	シスメックス株式会社	新規人工核酸、その製造方法及び用途
US20220213484A1 (en)	2019-04-03	2022-07-07	Bristol-Myers Squibb Company	Angptl2 antisense oligonucleotides and uses thereof
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
JP7499267B2 (ja)	2019-04-04	2024-06-13	エフ．ホフマン－ラロシュアーゲー	Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
CN113661168A (zh)	2019-04-16	2021-11-16	罗氏创新中心哥本哈根有限公司	用于制备核苷酸p(v)单体的新方法
JP2022530537A (ja)	2019-04-30	2022-06-29	ロシュイノベーションセンターコペンハーゲンエーエス	レニウムキレート化ｍａｇ３オリゴヌクレオチドを調製するための新規の方法
KR20220004675A (ko)	2019-05-03	2022-01-11	다이서나 파마수이티컬, 인크.	단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자
WO2020236600A1 (en)	2019-05-17	2020-11-26	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
CN113950529A (zh)	2019-06-06	2022-01-18	豪夫迈·罗氏有限公司	靶向atxn3的反义寡核苷酸
CA3142593A1 (en) *	2019-06-19	2020-12-24	Yamasa Corporation	Crosslinked nucleoside intermediate crystal and method for producing same, and method for producing crosslinked nucleoside amidite
EP3995153A4 (en)	2019-06-26	2023-11-22	KNC Laboratories Co., Ltd.	NUCLEIC ACID DRUG SUPPRESSING MYOSTATIN GENE MRNA PRODUCTION
EP3997225A1 (en)	2019-07-10	2022-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of epilepsy
EP3998108A4 (en)	2019-07-12	2024-10-30	Daiichi Sankyo Co Ltd	ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING THE SPLICING OF DUX4 PRE-MRNA
US20220267737A1 (en)	2019-07-18	2022-08-25	University Of Rochester	Cell-type selective immunoprotection of cells
EP3956450A4 (en)	2019-07-26	2022-11-16	Ionis Pharmaceuticals, Inc.	COMPOUNDS AND METHODS FOR MODULATION OF GFAP
WO2021030768A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with stat3-antisense oligonucleotides
KR20220070433A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Stat6을 표적으로 하는 세포외 소포-aso 작제물
EP4013876A1 (en)	2019-08-14	2022-06-22	Codiak BioSciences, Inc.	Extracellular vesicle-nlrp3 antagonist
JP2022544288A (ja)	2019-08-14	2022-10-17	コディアックバイオサイエンシーズ，インコーポレイテッド	ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物
EP4013457A1 (en)	2019-08-14	2022-06-22	Codiak BioSciences, Inc.	Extracellular vesicle linked to molecules and uses thereof
CA3147701A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with antisense oligonucleotides targeting kras
EP4013767A4 (en)	2019-08-15	2023-10-25	Ionis Pharmaceuticals, Inc.	COMPOUND-MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
JPWO2021049504A1 (tr)	2019-09-10	2021-03-18
WO2021062058A1 (en)	2019-09-25	2021-04-01	Codiak Biosciences, Inc.	Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021074657A1 (en)	2019-10-17	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination treatment for cystic fibrosis
TW202128704A (zh)	2019-10-18	2021-08-01	日商第一三共股份有限公司	雙環亞磷醯胺之製造方法
CN111109591A (zh)	2019-10-25	2020-05-08	新疆红旗坡农业发展集团有限公司	肠道微生态高效重建型苹果酵素及加工技术
JP2023500681A (ja)	2019-11-06	2023-01-10	アルニラムファーマスーティカルズインコーポレイテッド	肝臓外送達
EP4055165A1 (en)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
EP4061943A1 (en)	2019-11-19	2022-09-28	Institut National de la Santé et de la Recherche Médicale (INSERM)	Antisense oligonucleotides and their use for the treatment of cancer
CN114829601A (zh)	2019-12-19	2022-07-29	豪夫迈·罗氏有限公司	Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
EP4077667A1 (en)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Use of sept9 inhibitors for treating hepatitis b virus infection
WO2021122921A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of cops3 inhibitors for treating hepatitis b virus infection
EP4077671A1 (en)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Use of saraf inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of scamp3 inhibitors for treating hepatitis b virus infection
CN114829603A (zh)	2019-12-20	2022-07-29	豪夫迈·罗氏有限公司	用于抑制scn9a表达的增强寡核苷酸
CN114828852A (zh)	2019-12-24	2022-07-29	豪夫迈·罗氏有限公司	用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
JP2023509870A (ja)	2019-12-24	2023-03-10	エフ．ホフマン－ラロシュアーゲー	Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ
WO2021158810A1 (en)	2020-02-05	2021-08-12	Bristol-Myers Squibb Company	Oligonucleotides for splice modulation of camk2d
CN115176010A (zh)	2020-02-28	2022-10-11	豪夫迈·罗氏有限公司	用于调节cd73外显子7剪接的寡核苷酸
CA3175125A1 (en)	2020-03-11	2021-09-16	Biocomber Co., Ltd.	Single-stranded nucleic acid molecule for inducing -1 frameshift and composition
WO2021184021A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Methods of treating neuroinflammation
WO2021198883A1 (en)	2020-03-31	2021-10-07	Janssen Biopharma, Inc.	Synthesis of oligonucleotides and related compounds
EP4149486A1 (en)	2020-05-11	2023-03-22	Genentech, Inc.	Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021231204A1 (en)	2020-05-11	2021-11-18	Genentech, Inc.	Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
EP4150085A1 (en)	2020-05-11	2023-03-22	Genentech, Inc.	Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
AU2021270720A1 (en)	2020-05-11	2022-12-08	Stoke Therapeutics, Inc.	OPA1 antisense oligomers for treatment of conditions and diseases
JP2023526267A (ja)	2020-05-13	2023-06-21	エフ．ホフマン－ラロシュアーゲー	プログラニュリン標的オリゴヌクレオチドアゴニスト
US20230193269A1 (en)	2020-05-22	2023-06-22	Boehringer Ingelheim International Gmbh	Oligonucleotides for splice modulation of card9
JP2023529457A (ja)	2020-06-09	2023-07-10	ロシュイノベーションセンターコペンハーゲンエーエス	治療用ポリヌクレオチドに使用するためのグアノシン類似体
AR122731A1 (es)	2020-06-26	2022-10-05	Hoffmann La Roche	Oligonucleótidos mejorados para modular la expresión de fubp1
EP4179091A1 (en)	2020-07-10	2023-05-17	Institut National De La Sante Et De La Recherche Medicale - Inserm	Methods and compositions for treating epilepsy
WO2022018155A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Lna oligonucleotides for splice modulation of stmn2
EP4185696A1 (en)	2020-07-23	2023-05-31	F. Hoffmann-La Roche AG	Oligonucleotides targeting rna binding protein sites
CN115916976A (zh)	2020-07-28	2023-04-04	神户天然物化学株式会社	诱导血管紧张素转换酶2基因外显子跳跃的反义核酸
JP2023538630A (ja)	2020-08-21	2023-09-08	エフ．ホフマン－ラロシュアーゲー	Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
WO2022043531A1 (en) *	2020-08-28	2022-03-03	Janssen Sciences Ireland Unlimited Company	7'-substituted 2'-o-4'-c-ethylene-bridged nucleic acid (ena) monomers and uses thereof
CN116322706A (zh)	2020-09-25	2023-06-23	株式会社理真思	新人工核酸、其制造方法和用途
US20230364127A1 (en)	2020-10-06	2023-11-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
WO2022117745A1 (en)	2020-12-03	2022-06-09	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting atxn3
AR124227A1 (es)	2020-12-03	2023-03-01	Hoffmann La Roche	Oligonucleótidos antisentido que actúan sobre atxn3
JP2023553069A (ja)	2020-12-08	2023-12-20	エフ．ホフマン－ラロシュアーゲー	ホスホロジチオエートオリゴヌクレオチドの新規合成
TW202229553A (zh)	2020-12-18	2022-08-01	瑞士商赫孚孟拉羅股份公司	靶向顆粒蛋白前體之反義寡核苷酸
JP2024501662A (ja)	2020-12-22	2024-01-15	エフ．ホフマン－ラロシュアーゲー	Ｘｂｐ１を標的とするオリゴヌクレオチド
IL304048A (en) *	2020-12-31	2023-08-01	Dyne Therapeutics Inc	Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
WO2022147223A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
WO2022147214A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
TW202246500A (zh)	2021-02-02	2022-12-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｒｔｅｌ１表現之增強型寡核苷酸
JP2024512236A (ja)	2021-02-17	2024-03-19	ロンザセールスアーゲー	細胞外ベシクル－ｎｌｒｐ３アンタゴニスト
EP4294456A1 (en)	2021-02-17	2023-12-27	Lonza Sales AG	Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
JPWO2022181532A1 (tr)	2021-02-26	2022-09-01
EP4314016A1 (en)	2021-03-31	2024-02-07	Entrada Therapeutics, Inc.	Cyclic cell penetrating peptides
WO2022241408A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating tissue distribution of intracellular therapeutics
JP2024513841A (ja)	2021-04-01	2024-03-27	ロンザセールスアーゲー	細胞外小胞組成物
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
CA3217463A1 (en)	2021-05-10	2022-11-17	Ziqing QIAN	Compositions and methods for modulating mrna splicing
WO2022258555A1 (en)	2021-06-08	2022-12-15	F. Hoffmann-La Roche Ag	Oligonucleotide progranulin agonists
IL309001A (en)	2021-06-23	2024-02-01	Entrada Therapeutics Inc	Antisense compounds and methods for targeting CUG repeats
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4367237A2 (en)	2021-07-09	2024-05-15	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
US11633498B2 (en)	2021-07-09	2023-04-25	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024526890A (ja)	2021-07-21	2024-07-19	アルナイラムファーマシューティカルズ，インコーポレイテッド	代謝障害関連標的遺伝子ｉｒｎａ組成物およびその使用方法
WO2023021046A1 (en)	2021-08-16	2023-02-23	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2023026994A1 (ja)	2021-08-21	2023-03-02	武田薬品工業株式会社	ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
WO2023034817A1 (en)	2021-09-01	2023-03-09	Entrada Therapeutics, Inc.	Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
EP4408999A1 (en)	2021-09-29	2024-08-07	F. Hoffmann-La Roche AG	Rna editing
EP4416284A1 (en)	2021-10-15	2024-08-21	Alnylam Pharmaceuticals, Inc.	Extra-hepatic delivery irna compositions and methods of use thereof
WO2023078883A1 (en)	2021-11-03	2023-05-11	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating apolipoprotein e4 expression
KR20240101580A (ko)	2021-11-11	2024-07-02	에프. 호프만-라 로슈 아게	Hbv 치료를 위한 약학 조합물
WO2023104693A1 (en)	2021-12-07	2023-06-15	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
WO2023111336A1 (en)	2021-12-17	2023-06-22	F. Hoffmann-La Roche Ag	Oligonucleotide gba agonists
EP4448106A1 (en)	2021-12-17	2024-10-23	Hoffmann-La Roche Inc.	Combination of oligonucleotides for modulating rtel1 and fubp1
CN118434860A (zh)	2021-12-20	2024-08-02	豪夫迈·罗氏有限公司	苏糖核酸反义寡核苷酸及其方法
EP4453211A1 (en)	2021-12-22	2024-10-30	Camp4 Therapeutics Corporation	Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2023127857A1 (ja)	2021-12-27	2023-07-06	株式会社理研ジェネシス	新規人工核酸、その製造方法及び用途
CN118613268A (zh)	2022-01-20	2024-09-06	基因泰克公司	用于调节tmem106b表达的反义寡核苷酸
WO2023150553A1 (en)	2022-02-01	2023-08-10	University Of Rochester	Gpr17 promoter-based targeting and transduction of glial progenitor cells
WO2023152369A1 (en)	2022-02-14	2023-08-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20240167040A1 (en)	2022-02-21	2024-05-23	Hoffmann-La Roche Inc.	Antisense oligonucleotide
WO2023176862A1 (ja)	2022-03-16	2023-09-21	第一三共株式会社	トランスフェリン受容体２の発現を抑制するｓｉＲＮＡ
TW202400786A (zh)	2022-03-16	2024-01-01	日商第一三共股份有限公司	具有RNAi活性的化學修飾寡核苷酸
AU2023254846A1 (en)	2022-04-15	2024-10-10	Dyne Therapeutics, Inc.	Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2023217890A1 (en)	2022-05-10	2023-11-16	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting cfp-elk1 intergene region
WO2023220744A2 (en)	2022-05-13	2023-11-16	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
TW202409276A (zh)	2022-05-18	2024-03-01	瑞士商赫孚孟拉羅股份公司	改良之靶向ｒｎａ結合蛋白位點的寡核苷酸
WO2023240277A2 (en)	2022-06-10	2023-12-14	Camp4 Therapeutics Corporation	Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
WO2023242324A1 (en)	2022-06-17	2023-12-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for targeting progranulin
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024017990A1 (en)	2022-07-21	2024-01-25	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating chronic pain disorders
WO2024026474A1 (en)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024040041A1 (en)	2022-08-15	2024-02-22	Dicerna Pharmaceuticals, Inc.	Regulation of activity of rnai molecules
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
EP4332221A1 (en)	2022-08-29	2024-03-06	Roche Innovation Center Copenhagen A/S	Threose nucleic acid antisense oligonucleotides and methods thereof
TW202421206A (zh)	2022-09-06	2024-06-01	瑞士商赫孚孟拉羅股份公司	用於投予至眼睛之雙股ｒｎａ分子
WO2024073732A1 (en)	2022-09-30	2024-04-04	Alnylam Pharmaceuticals, Inc.	Modified double-stranded rna agents
WO2024098061A2 (en)	2022-11-04	2024-05-10	Genkardia Inc.	Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024098002A1 (en)	2022-11-04	2024-05-10	Regeneron Pharmaceuticals, Inc.	Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
US20240173426A1 (en)	2022-11-14	2024-05-30	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024119145A1 (en)	2022-12-01	2024-06-06	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024126654A1 (en)	2022-12-14	2024-06-20	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
WO2024146935A1 (en)	2023-01-06	2024-07-11	Institut National de la Santé et de la Recherche Médicale	Intravenous administration of antisense oligonucleotides for the treatment of pain
WO2024160756A1 (en)	2023-01-30	2024-08-08	Vib Vzw	Suppressors of tauopathies
WO2024168010A2 (en)	2023-02-09	2024-08-15	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
WO2024175588A1 (en)	2023-02-21	2024-08-29	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2024175586A2 (en)	2023-02-21	2024-08-29	Vib Vzw	Inhibitors of synaptogyrin-3 expression
WO2024216155A1 (en)	2023-04-12	2024-10-17	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery of double-stranded rna agents
CN117510564B (zh) *	2024-01-08	2024-03-08	苏州诺维康生物科技有限公司	一种医药中间体N2-Ac-5'-O-DMT-2'-O-炔丙基鸟苷的合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
NZ209840A (en)	1983-10-17	1988-11-29	Kaji Akira	A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5194428A (en)	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en)	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5004810A (en)	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5457189A (en)	1989-12-04	1995-10-10	Isis Pharmaceuticals	Antisense oligonucleotide inhibition of papillomavirus
US5591623A (en)	1990-08-14	1997-01-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5514788A (en)	1993-05-17	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5620963A (en)	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en)	1990-02-26	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide therapies for modulating the effects of herpes viruses
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5591720A (en)	1990-08-16	1997-01-07	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating the effects of cytomegalovirus infections
HUT69956A (en)	1990-08-14	1995-09-28	Isis Pharmaceuticals Inc	Methode for inhibition of influenza virus by antiseuse oligonucleotides
US6111094A (en)	1990-08-14	2000-08-29	Isis Pharmaceuticals Inc.	Enhanced antisense modulation of ICAM-1
US5442049A (en)	1992-11-19	1995-08-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating the effects of cytomegalovirus infections
US5691461A (en)	1990-08-16	1997-11-25	Isis Pharmaceuticals, Inc.	Oligonucleotides inhibiting candida germ tube formation
JP2515230Y2 (ja) *	1990-08-31	1996-10-30	徹松井	道糸通し糸付き浮子
US5242906A (en)	1991-04-22	1993-09-07	University Of North Carolina At Chapel Hill	Antisense oligonucleotides against Epstein-Barr virus
WO1994008003A1 (en)	1991-06-14	1994-04-14	Isis Pharmaceuticals, Inc.	ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
EP0590082B1 (en)	1991-06-14	1999-10-27	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide inhibition of the ras gene
US5582986A (en)	1991-06-14	1996-12-10	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide inhibition of the ras gene
US5607923A (en)	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5661134A (en)	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5681747A (en)	1992-03-16	1997-10-28	Isis Pharmaceuticals, Inc.	Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5523389A (en)	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
US5985558A (en)	1997-04-14	1999-11-16	Isis Pharmaceuticals Inc.	Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
PT820483E (pt)	1995-04-07	2001-03-30	Mogens Havsteen Jakobsen	Metodo de imobilizacao fotoquimica de ligandos usando quinonas
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
WO1998039532A1 (en) *	1997-03-07	1998-09-11	Kværner Oilfield Products A.S	Termination of a tension member, for use as a tendon for a tension leg platform
JP3756313B2 (ja) *	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US5877309A (en)	1997-08-13	1999-03-02	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against JNK
US7572582B2 (en)	1997-09-12	2009-08-11	Exiqon A/S	Oligonucleotide analogues
AU9063398A (en) *	1997-09-12	1999-04-05	Exiqon A/S	Oligonucleotide analogues
US6794499B2 (en) *	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US5955443A (en)	1998-03-19	1999-09-21	Isis Pharmaceuticals Inc.	Antisense modulation of PECAM-1
US7084125B2 (en) *	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
ES2283298T3 (es) *	1999-05-04	2007-11-01	Santaris Pharma A/S	Analogos de l-ribo-lna.
JP4151751B2 (ja)	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
KR20070112295A (ko)	1999-09-10	2007-11-22	제론 코포레이션	올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
EP1783216A1 (en)	2004-05-28	2007-05-09	Sankyo Company, Limited	Telomerase-inhibitory ena oligonucleotide

2000
- 2000-02-10 TR TR2001/02328T patent/TR200102328T2/tr unknown
- 2000-02-10 EP EP00902887.9A patent/EP1152009B2/en not_active Expired - Lifetime
- 2000-02-10 DK DK00902887.9T patent/DK1152009T4/en active
- 2000-02-10 RU RU2001124910/04A patent/RU2233844C2/ru active
- 2000-02-10 AT AT00902887T patent/ATE287897T2/de active
- 2000-02-10 AU AU24598/00A patent/AU758956B2/en not_active Expired
- 2000-02-10 CN CNB008056277A patent/CN1273478C/zh not_active Expired - Lifetime
- 2000-02-10 CA CA002361318A patent/CA2361318C/en not_active Expired - Lifetime
- 2000-02-10 ES ES00902887.9T patent/ES2234563T5/es not_active Expired - Lifetime
- 2000-02-10 CZ CZ20012574A patent/CZ296576B6/cs not_active IP Right Cessation
- 2000-02-10 HU HU0105367A patent/HU228398B1/hu unknown
- 2000-02-10 KR KR1020017009992A patent/KR100573231B1/ko active IP Right Grant
- 2000-02-10 ID IDW00200101604A patent/ID30093A/id unknown
- 2000-02-10 BR BRPI0008131A patent/BRPI0008131B8/pt not_active IP Right Cessation
- 2000-02-10 PT PT00902887T patent/PT1152009E/pt unknown
- 2000-02-10 DE DE60017711.4T patent/DE60017711T3/de not_active Expired - Lifetime
- 2000-02-10 IL IL14433800A patent/IL144338A0/xx unknown
- 2000-02-10 NZ NZ513402A patent/NZ513402A/xx not_active IP Right Cessation
- 2000-02-10 PL PL349570A patent/PL208245B1/pl unknown
- 2000-02-10 TR TR2006/042112006/04211T patent/TR200604211T1/tr unknown
- 2000-02-10 WO PCT/JP2000/000725 patent/WO2000047599A1/ja active Application Filing
- 2000-02-11 TW TW089102314A patent/TW513438B/zh not_active IP Right Cessation
- 2000-02-14 JP JP2000034560A patent/JP3420984B2/ja not_active Expired - Lifetime
2001
- 2001-07-16 IL IL144338A patent/IL144338A/en not_active IP Right Cessation
- 2001-08-08 ZA ZA200106544A patent/ZA200106544B/en unknown
- 2001-08-09 US US09/925,673 patent/US7335765B2/en not_active Expired - Lifetime
- 2001-08-10 NO NO20013899A patent/NO320441B1/no not_active IP Right Cessation
2002
- 2002-02-26 HK HK02101460.7A patent/HK1040084B/zh not_active IP Right Cessation
2003
- 2003-05-05 US US10/430,705 patent/US7314923B2/en not_active Expired - Lifetime
2007
- 2007-07-27 US US11/881,775 patent/US7816333B2/en not_active Expired - Fee Related
2010
- 2010-07-22 US US12/804,500 patent/US8957201B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK1152009T3 (da)	2005-03-07
ATE287897T2 (de)	2005-02-15
KR20020013498A (ko)	2002-02-20
TR200604211T1 (tr)	2007-02-21
TW513438B (en)	2002-12-11
DE60017711T3 (de)	2018-01-11
DE60017711T2 (de)	2005-11-17
BRPI0008131B1 (pt)	2016-12-27
CZ296576B6 (cs)	2006-04-12
CZ20012574A3 (cs)	2002-02-13
ES2234563T5 (es)	2018-01-17
NO20013899D0 (no)	2001-08-10
JP2000297097A (ja)	2000-10-24
EP1152009B2 (en)	2017-09-06
HUP0105367A3 (en)	2005-10-28
AU2459800A (en)	2000-08-29
CA2361318A1 (en)	2000-08-17
KR100573231B1 (ko)	2006-04-24
EP1152009A1 (en)	2001-11-07
US7816333B2 (en)	2010-10-19
RU2233844C2 (ru)	2004-08-10
NO20013899L (no)	2001-10-10
US7314923B2 (en)	2008-01-01
US20090149404A1 (en)	2009-06-11
US20020147332A1 (en)	2002-10-10
TR200102328T2 (tr)	2002-01-21
IL144338A (en)	2013-11-28
IL144338A0 (en)	2002-05-23
DK1152009T4 (en)	2017-12-11
EP1152009B1 (en)	2005-01-26
US20030207841A1 (en)	2003-11-06
ZA200106544B (en)	2002-11-08
CN1273478C (zh)	2006-09-06
BR0008131A (pt)	2002-04-09
ES2234563T3 (es)	2005-07-01
HUP0105367A2 (hu)	2002-05-29
US8957201B2 (en)	2015-02-17
US7335765B2 (en)	2008-02-26
BRPI0008131B8 (pt)	2021-05-25
WO2000047599A1 (fr)	2000-08-17
ID30093A (id)	2001-11-01
US20110009471A1 (en)	2011-01-13
NZ513402A (en)	2003-06-30
DE60017711D1 (de)	2005-03-03
PT1152009E (pt)	2005-03-31
HK1040084B (zh)	2005-04-22
CA2361318C (en)	2008-11-25
CN1347418A (zh)	2002-05-01
EP1152009A4 (en)	2002-06-05
HU228398B1 (en)	2013-03-28
HK1040084A1 (en)	2002-05-24
PL208245B1 (pl)	2011-04-29
AU758956B2 (en)	2003-04-03
JP3420984B2 (ja)	2003-06-30

Legal Events

Date	Code	Title	Description
2014-04-14	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: DAIICHI SANKYO CO LTD, JP
2020-03-09	MK1K	Patent expired

Publication	Publication Date	Title
NO320441B1 (no)	2005-12-05	Nukleosider, oligonukleotidanaloger, farmasoytiske preparater, prober for gener, primere for amplifikasjon og anvendelse av oligonukleotidanaloger til fremstilling av medikamenter
EP1218391B1 (en)	2007-04-11	Compounds for protecting hydroxyls and methods for their use
JP3756313B2 (ja)	2006-03-15	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US20040143114A1 (en)	2004-07-22	Novel bicyclonucleoside analogues
US20040132684A1 (en)	2004-07-08	Polymeric nucleoside prodrugs
US7982030B2 (en)	2011-07-19	Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
JP2002543215A (ja)	2002-12-17	Ａ−ｄｎａ型およびｂ−ｄｎａ型立体配座幾何学形状を有するオリゴヌクレオチド
EP2370451A2 (en)	2011-10-05	Method for the synthesis of phosphorus atom modified nucleic acids
US20240343752A1 (en)	2024-10-17	Novel bicyclic nucleosides and oligomers prepared therefrom
JP2002520420A (ja)	2002-07-09	部位特異的キラルホスホロチオエート・ヌクレオシド間結合を有するオリゴヌクレオチド
EP0948514B1 (en)	2005-04-27	Method for the synthesis of nucleotide or oligonucleotide phosphoramidites
EP2053054B1 (en)	2014-12-17	Method for introducing nucleic-acid-protecting group
JP2024534871A (ja)	2024-09-26	ｍＲＮＡキャップ類似体及びその用途
WO2000068241A1 (en)	2000-11-16	Processes for the synthesis of oligomers using phusphoramidite compositions
US6914052B2 (en)	2005-07-05	Selective anti-viral nucleoside chain terminators
JP2013531665A (ja)	2013-08-08	オリゴヌクレオチド合成のためにｎ−チオ化合物を用いる新規な方法
Filichev et al.	2002	Synthesis of a Thymidine Dimer Containing a Tetrazole‐2, 5‐diyl Internucleosidic Linkage and Its Insertion into Oligodeoxynucleotides
RU2824141C2 (ru)	2024-08-06	Новые бициклические нуклеозиды и олигомеры, полученные из них
Lin	2013	Oligodeoxynucleotide synthesis using protecting groups and a linker cleavable under non-nucleophilic conditions
US20150361124A1 (en)	2015-12-17	Method for the solid-phase based synthesis of phosphate-bridged nucleoside conjugates
Läppchen	1997	Synthesis of GTP analogues and evaluation of their effect on the antibiotic target FtsZ and its
MXPA01008145A (en)	2002-03-26	Novel nucleosides and oligonucleotide analogues